Global Oncology Drugs Market Size, Share & Industry Trends Analysis Report By Indication, By Drug Class Type (Targeted Therapy, Immunotherapy (Biologic Therapy), Chemotherapy and Hormonal Therapy), By Regional Outlook and Forecast, 2023 - 2030

The Global Oncology Drugs Market size is expected to reach $273.3 billion by 2030, rising at a market growth of 7.7% CAGR during the forecast period.

Advances in understanding stomach cancer's molecular and genetic characteristics enable the development of more personalized and individualized treatment plans. Consequently, the Stomach Cancer segment captured $13,239.3 million revenue in the market in 2022. Stomach cancer remains a significant global health concern, and efforts in early detection, research, and advancements in treatment modalities are critical for improving outcomes for individuals affected by this disease. Regular screenings, awareness of risk factors, and prompt medical attention for persistent symptoms can contribute to early diagnosis and better treatment outcomes. Oncologists can tailor therapy based on the specific profile of the patient's cancer, optimizing the chances of treatment success.

The major strategies followed by the market participants are Partnerships, Collaborations & Agreements as the key developmental strategy to keep pace with the changing demands of end users. For instance, In September, 2023, Merck & Co., Inc. collaborations with BenevolentAI, London, U.K., and Exscientia, Oxford, U.K., to produce novel clinical development drug candidates with first-in-class and best-in-class potential in oncology, neurology, and immunology. Additionally, In June, 2023, Astellas Pharma Inc. and Cullgen Inc. came into collaboration to develop targeted protein degraders by combining Cullgen's uSMITE platform with novel E3 ligands and Astellas' drug discovery capabilities.

KBV Cardinal Matrix - Market Competition Analysis

Based on the Analysis presented in the KBV Cardinal matrix; Pfizer Inc. is the forerunners in the Oncology Drugs Market. For Instance, In September, 2022, Pfizer extended its partnership with CytoReason, to use CytoReason’s artificial intelligence technology for Pfizer’s drug development programs. Under the terms of the agreement, Pfizer will make a $20M equity investment, have options to license CytoReason’s platform and disease models, and fund supplementary project support, in a deal potentially worth up to $110M over the next five years. Companies such as AbbVie, Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd. are some of the key innovators in the Market.

COVID-19 Impact Analysis

The COVID-19 pandemic had significantly influenced the oncology drugs market. The pandemic led to disruptions in the manufacturing and supply chains of pharmaceuticals globally. Lockdowns, travel restrictions, and workforce shortages impeded the production and distribution of oncology drugs. Many pharmaceutical companies faced challenges in securing raw materials, transporting finished products, and maintaining regular production schedules, leading to potential shortages and delays in the availability of cancer medications. Clinical trials play a pivotal role in bringing new oncology drugs to market. This interruption in research activities delayed the developing and approval of novel cancer therapies. The oncology drugs market is engaged in resilience planning as the world moves toward a post-pandemic phase. This involves strategies to mitigate future disruptions, enhance supply chain robustness, and improve the adaptability of healthcare systems to unforeseen challenges.

Market Growth Factors

Rise in the prevalence of cancer globally

For Instance, Cancer is the primary cause of death on a global scale, accounting for nearly 10 million deaths in 2020, according to the WHO. In 2020, the following cancer types accounted for the majority of cases: breast (2.26 million cases), lung (2.21 million cases), colon and rectum (1.93 million cases), prostate (1.41 million cases), epidermis (1.20 million cases excluding melanoma), and stomach (1.09 million cases). Advances in cancer screening technologies and awareness programs have led to increased early detection of cancer. Early diagnosis often results in more effective treatment options, driving the demand for oncology drugs. Heightened awareness about cancer, facilitated by patient advocacy groups and educational initiatives, has improved understanding of risk factors, early symptoms, and the importance of timely medical intervention. This awareness contributes to a proactive approach to cancer management, driving the demand for effective oncology drugs. The rise in the number of cancers globally has profound implications for the market.

Surge in the global geriatric population

However, WHO estimates that by 2030, one in every six individuals will be sixty or older. By 2020, the proportion of the population aged 60 and older will have increased from one billion to 1.4 billion. The global population of individuals 60 and above is projected to increase twofold to 2.1 billion by 2050. The senior population often experiences a higher burden of cancer-related symptoms and side effects of therapy. Oncology drugs that address symptoms, improve quality of life, and provide palliative care become essential components of cancer care for older adults. Increased awareness about cancer in the genetic population, along with advocacy efforts, has led to a greater comprehension of the unique challenges faced by older cancer patients. This awareness contributes to a more comprehensive approach to cancer care, focusing on tailored drug therapies. The surge in the global geriatric population significantly expands the oncology drugs market, necessitating the development of targeted and specialized treatments for older adults with cancer.

Market Restraining Factors

Adverse effects associated with the usage of cancer drugs.

Many cancer drugs can cause toxicity in healthy tissues, leading to adverse effects such as nausea, vomiting, fatigue, and hair loss. The severity of these toxicities can vary and managing them effectively is crucial to ensure patient comfort and compliance with treatment regimens. Certain cancer drugs, particularly chemotherapy, can suppress the immune system, making patients more sensitive to infections. Some cancer drugs, particularly certain chemotherapies, and targeted therapies, can have adverse effects on the heart, leading to cardiotoxicity. Monitoring and managing cardiotoxicity are essential to prevent long-term cardiovascular complications. Adverse effects of cancer drugs can have a significant psychosocial impact on patients, leading to anxiety, depression, and changes in body image. Addressing the psychosocial factors of cancer care is crucial for holistic patient support. These factors will decline the market growth in the coming years.

Indication Outlook

Based on indication, the market is fragmented into lung cancer, stomach cancer, colorectal cancer, breast cancer, prostate cancer, liver cancer, esophagus cancer, cervical cancer, kidney cancer, bladder cancer, and other cancer. The lung cancer segment garnered a significant revenue share in the market in 2022. The use of oncology drugs in lung cancer is closely tied to ongoing research and clinical trials. Oncology drugs have significantly improved the landscape of lung cancer treatment. From targeted therapies to immunotherapies and combination regimens, these drugs offer a range of benefits that address the complexities of lung cancer and contribute to better patient outcomes. The ongoing evolution of precision medicine and the development of innovative therapies hold promise for further advancements in lung cancer treatment.

Drug Class Type Outlook

On the basis of drug class type, the market is segmented into chemotherapy, targeted therapy, immunotherapy (biologic therapy), and hormonal therapy. In 2022, the targeted therapy segment dominated the oncology drugs market with maximum revenue share. This is attributed to identifying molecular targets of cancer cells, fewer adverse effects, and the availability of several targeted therapeutics. Recent developments in cellular technology have enhanced the molecular comprehension of tumor cells and their metabolism, thereby increasing the demand for targeted drug therapies to treat cancer. On the contrary, market growth is anticipated to be most rapid in the need for immunotherapy over the projected period, owing to its efficacy and the expected launch of pipeline immunotherapies.

Oncology Drugs Market Report Coverage

Report Attribute	Details
Market size value in 2022	USD 152.4 Billion
Market size forecast in 2030	USD 273.3 Billion
Base Year	2022
Historical Period	2019 to 2021
Forecast Period	2023 to 2030
Revenue Growth Rate	CAGR of 7.7% from 2023 to 2030
Number of Pages	290
Number of Table	353
Report coverage	Market Trends, Revenue Estimation and Forecast, Segmentation Analysis, Regional and Country Breakdown, Competitive Landscape, Porter’s 5 Forces Analysis, Company Profiling, Companies Strategic Developments, SWOT Analysis, Winning Imperatives
Segments covered	Indication, Drug Class Type, Region
Country scope	North America (US, Canada, Mexico, and Rest of North America) Europe (Germany, UK, France, Russia, Spain, Italy, and Rest of Europe) Asia Pacific (China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific) LAMEA (Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA)
Companies Included	AbbVie, Inc., Amgen, Inc., Astellas Pharma, Inc., AstraZeneca PLC, Bristol Myers Squibb Company, F. Hoffmann-La Roche Ltd., Johnson & Johnson, Novartis AG, Merck & Co., Inc. and Pfizer Inc.
Growth Drivers	Rise in the prevalence of cancer globally Surge in the global geriatric population
Restraints	Adverse effects associated with the usage of cancer drugs.

Regional Outlook

Region-wide, the market is further divided into North America, Europe, Asia Pacific and LAMEA. The Asia Pacific region acquired a substantial revenue share in the market in 2022. The rapidly rising rate of the senior population and increasing demand for improved healthcare facilities, especially in developing countries in the region, are some of the market drivers. The presence of big pharmaceutical industries like India and China will also boost the regional market growth. China is owing to the greater government spending on improving healthcare facilities within the region and the government's initiative to enhance the production of high-quality pharmaceuticals within the country.

Free Valuable Insights: Global Oncology Drugs Market size to reach USD 273.3 Billion by 2030

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include AbbVie, Inc., Amgen, Inc., Astellas Pharma, Inc., AstraZeneca PLC, Bristol Myers Squibb Company, F. Hoffmann-La Roche Ltd., Johnson & Johnson, Novartis AG, Merck & Co., Inc. and Pfizer Inc.

Strategies deployed in the Market

» Partnerships, Collaborations, and Agreements:

• Nov-2023: Astellas Pharma Inc. and Propella Therapeutics, Inc. announced the completion of a merger agreement, with Astellas acquiring Propella, a privately held biopharmaceutical company, utilized a proprietary platform combining medicinal chemistry with lymphatic targeting to develop new oncology drugs.
• Sep-2023: Bristol Myers Squibb Company and Samsung Biologics, a South Korean biotechnology company, signed an agreement for large-scale manufacturing of a Bristol Myers Squibb commercial antibody cancer drug substance. Under the new agreement, Samsung Biologics provided drug substance manufacturing at its latest and largest biomanufacturing facility, Plant 4, in Songdo, South Korea.
• Sep-2023: F. Hoffmann-La Roche Ltd. expanded its collaboration with Janssen Biotech Inc. to develop companion diagnostics for targeted therapies, enhancing research and innovation. The expanded agreement provided broader opportunities for collaboration in precision medicine, incorporating various companion diagnostics technologies like immunohistochemistry (IHC), digital pathology, next-generation sequencing, polymerase chain reaction, and immunoassays.
• 2023-Sep: Merck & Co., Inc. announced strategic drug discovery collaborations with BenevolentAI, London, U.K., and Exscientia, Oxford, U.K., utilizing AI-driven design and discovery capabilities to advance research. The partnerships aimed to produce novel clinical development drug candidates with first-in-class and best-in-class potential in oncology, neurology, and immunology.
• Sep-2023: Merck & Co., Inc., and the Institute of Cancer Research (ICR) renewed their strategic collaboration to discover and develop cancer therapeutics. Researchers from the institute's Centre for Cancer Drug Discovery collaborated with Merck to develop small-molecule inhibitors targeting a new class of cancer targets, with both parties contributing staff and financial resources for the partnership.
• Jun-2023: Astellas Pharma Inc. and Cullgen Inc., a privately held biopharmaceutical company, came into collaboration and exclusive option agreement to discover innovative protein degraders. The partnership aimed to develop targeted protein degraders by combining Cullgen's uSMITE platform with novel E3 ligands and Astellas' drug discovery capabilities.
• May-2023: Astellas Pharma Inc. and Sony Corporation, a conglomerate that specializes in the development, design, production, manufacture, and sale of an electronic equipment, collaborated to develop a novel Antibody-Drug Conjugate (ADC) platform in oncology, utilizing Sony's unique polymeric material, "KIRAVIATM Backbone." The goal was to selectively deliver anti-cancer drugs to target cells, enhancing efficacy while minimizing side effects. The research aimed to create high-performing ADCs with stable drug delivery and a high Drug-to-Antibody Ratio (DAR).
• May-2023: Janssen Biotech, part of Johnson & Johnson's Janssen Pharmaceutical Companies, collaborated with Cellular Biomedicine Group, a biomedicine company, develops treatments for cancerous and degenerative diseases in Greater China, to develop and commercialize next-gen CAR T-cell therapies for B-cell malignancies. The investigational CD20-directed CAR-Ts exhibited promising responses in Phase 1 studies for relapsed/refractory non-Hodgkin’s lymphoma in China, particularly in diffuse large B-cell lymphoma cases.
• Feb-2023: AstraZeneca PLC expanded its partnership with Sophia Genetics, a data-driven medicine software company with headquarters in Lausanne, Switzerland, applying multimodal data management and analytics technology to oncology drug development. Using Sophia's DDM platform, they combined molecular data, imaging analysis, digital.
• Jan-2023: AbbVie, Inc. and Immunome, Inc., a clinical-stage biopharmaceutical company, announced a worldwide collaboration and option agreement to discover up to 10 novel antibody-target pairs from three specified tumour types using Immunome's Discovery Engine. The collaboration aimed to unlock novel cancer biology, potentially yielding multiple therapeutic candidates. The utilization of Immunome's Discovery Engine was anticipated to enhance AbbVie's existing oncology pipeline.
• Nov-2022: F. Hoffmann-La Roche Ltd. entered a second collaboration and license agreement with Jnana Therapeutics, a biotech company using its next-gen chemoproteomics platform for discovering small molecule drugs. The collaboration aimed to address diseases with high unmet needs, covering multiple targets from various target classes.
• Nov-2022: Pfizer Inc reached a settlement agreement with Glenmark Pharmaceuticals for the cancer treatment drug Axitinib Tablets (1 mg and 5 mg). The Mumbai-based drug maker and its US-based unit signed the settlement pact with Pfizer Inc.
• Oct-2022: F. Hoffmann-La Roche Ltd. and Hookipa Pharma, a clinical stage company developing products to prevent and cure infectious diseases and cancer., forged a strategic partnership and license agreement for the development of HB-700 and an undisclosed arenaviral immunotherapy. Hookipa conducted research and initial Phase Ib clinical development for HB-700 to treat KRAS-mutated cancers. Upon trial completion, Roche obtained the right to develop and market the licensed products across various indications, subject to approval.
• Sep-2022: Pfizer extended its partnership with CytoReason, a tech company developing a computational model of the human body, to use CytoReason’s artificial intelligence technology for Pfizer’s drug development programs. Under the terms of the agreement, Pfizer will make a $20M equity investment, have options to license CytoReason’s platform and disease models, and fund supplementary project support, in a deal potentially worth up to $110M over the next five years.
• Mar-2022: Novartis AG strategically collaborated with Lantheus Holdings, Inc., incorporating PYLARIFY® in prostate cancer clinical trials with Pluvicto (lutetium Lu 177 vipivotide tetraxetan). Under the agreement, Lantheus supplied PYLARIFY for patient selection, and Novartis shared all PYLARIFY-related clinical imaging data with Lantheus.
• Dec-2021: Novartis Pharma AG and BeiGene, Ltd. entered an option, collaboration, and license agreement for the development, manufacturing, and commercialization of BeiGene's TIGIT inhibitor ociperlimab in North America, Europe, and Japan. Additionally, BeiGene obtained rights to market and detail five approved Novartis oncology products—TAFINLAR (dabrafenib), MEKINIST (trametinib), VOTRIENT (pazopanib), AFINITOR (everolimus), and ZYKADIA (ceritinib)—across designated regions of China termed "broad markets."
• Jul-2021: Pfizer Inc. collaborated with Arvinas, Inc., a biopharmaceutical company that develops protein degradation therapeutics., to develop and commercialize ARV-471, an investigational oral PROTAC (PROteolysis TArgeting Chimera) estrogen receptor protein degrader. The collaboration leveraged Arvinas' targeted protein degradation leadership and Pfizer's global capabilities and breast cancer expertise, enhancing ARV-471's development and potential commercialization while advancing Arvinas' strategy.
• Mar-2021: Novartis AG came into collaboration with Artios Pharma Limited (Artios) in a global research initiative, exploring and validating next-generation DNA Damage Response (DDR) targets to enhance Novartis' Radioligand Therapies (RLT). In the three-year partnership, Artios and Novartis conducted target discovery and validation, with Novartis selecting up to three exclusive DDR targets. Novartis obtained worldwide rights to utilize these targets with its RLTs.
• Dec-2020: AbbVie, Inc. and Frontier Medicines, Corp. announced a global strategic collaboration to discover, develop, and commercialize innovative small molecule therapeutics against challenging protein targets. The collaboration utilized Frontier's chemo proteomics platform to identify small molecules for targeting novel E3 ligases, oncology, and immunology targets. Unlike conventional methods, this approach offered the potential to target a broader range of proteins.
• Dec-2020: Pfizer Inc. and Myovant Sciences, helps women with uterine fibroids and endometriosis and men with prostate cancer by developing new medicines, collaborated to develop and commercialize relugolix, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist, in oncology and women's health in the U.S. and Canada. Pfizer gained an exclusive option for relugolix commercialization in oncology outside the U.S. and Canada, excluding specific Asian countries.
• Oct-2020: Novartis AG partnered with Molecular Partners AG, a clinical-stage biopharmaceutical company based in Zürich, Switzerland, to develop and commercialize the anti-COVID-19 DARPin program, featuring candidates MP0420 and MP0423, aiming to expedite development using Molecular Partners' DARPin technologies and Novartis' expertise in drug development and commercialization in response to the urgent global need during the pandemic.
• Sep-2020: AbbVie, Inc. and I-Mab, a global biotechnology company, signed a global collaboration agreement for the development and commercialization of lemzoparlimab (TJC4), an anti-CD47 monoclonal antibody developed by I-Mab for treating various cancers. The agreement also included the potential expansion of collaboration to additional transformative therapies.
• Jun-2020: AbbVie, Inc. and Genmab A/S, an international biotech company specializing in creation and development of differentiated antibody therapeutics for treatment of cancer., concluded a collaboration to jointly develop and commercialize three early-stage bispecific antibody candidates and explore future antibody therapeutics for cancer. This partnership combined Genmab's expertise with AbbVie's clinical experience and innovative platforms.
• Jun-2020: Roche Pharma India, a subsidiary of F. Hoffmann-La Roche Ltd., extended its partnership with Cipla, a Mumbai-based multinational pharmaceutical company. This expanded collaboration included marketing and distribution of Roche's oncology drugs - trastuzumab (Herclon), bevacizumab (Avastin), and rituximab (Ristova) in India. The agreement aimed to maintain Roche's focus on providing innovations in India's healthcare system and fostering collaboration with stakeholders for improved patient outcomes.

» Product Launches and Product Expansions:

• Jun-2023: AstraZeneca PPLC launched its groundbreaking cancer medication, IMJUDO (tremelimumab), in the UAE. This move positioned the UAE as one of the first countries in the Middle East to provide access to the medication, signifying a notable advancement in cancer treatment. The drug demonstrated promising results, extending progression-free survival and overall survival rates, leading to improved treatment outcomes and a higher quality of life for patients.
• May-2022: F. Hoffmann-La Roche Ltd. introduced PHESGO, a drug for breast cancer treatment. PHESGO, the first fixed-dose formulation in oncology combining Perjeta and Herceptin with hyaluronidase, was administered via subcutaneous injection along with intravenous chemotherapy for early and metastatic breast cancer. The launch enhanced efficiency in healthcare systems, requiring less preparation and administration time, freeing up time for patients and healthcare professionals, and offering cost-saving benefits.

» Acquisitions and Mergers:

• Oct-2023: Bristol Myers Squibb Company and Mirati Therapeutics, Inc. finalized a merger agreement, with Bristol Myers Squibb acquiring Mirati. Through this acquisition, Bristol Myers Squibb added KRAZATI, a significant lung cancer medicine, to its commercial portfolio and gained access to promising clinical assets for its oncology pipeline and combination strategies.
• Apr-2023: Astellas Pharma Inc. and Iveric bio, Inc., a biopharmaceutical company focused on the discovery and development of novel treatment, entered a definitive agreement in which Astellas, through Berry Merger Sub, Inc., a wholly owned subsidiary of Astellas US Holding, Inc., acquired 100% of Iveric Bio's outstanding shares for $40.00 per share in cash, totalling approximately $5.9 billion in equity value. Iveric Bio became an indirectly wholly owned subsidiary of Astellas in the acquisition, considering approximately 148.2 million fully diluted outstanding shares of Iveric Bio common stock.
• Jan-2023: Merck & Co., Inc. completed the acquisition of Imago Biosciences, Inc. at a cash purchase price of $36.00 per share. Following the merger, Imago became a wholly owned subsidiary of Merck, and its common stock ceased trading on the Nasdaq Global Market.
• Dec-­2022: Johnson & Johnson announced that it completed its acquisition of Abiomed, a medical device technology company that operates as a stand-alone business within Johnson & Johnson's MedTech Segment. This acquisition marks another important step on Johnson & Johnson’s path to accelerating growth in our MedTech business and delivering innovative medical technologies to more people around the world.
• Oct­-2022: AbbVie, Inc. acquired DJS Antibodies Ltd, a UK biotech company focusing on developing antibodies for challenging disease-causing proteins. DJS-002, their lead program, aimed at treating Idiopathic Pulmonary Fibrosis (IPF) and other fibrotic diseases.
• Sep-2022: F. Hoffmann-La Roche Ltd. acquired Good Therapeutics, a US-based biopharmaceutical company, through a definitive merger agreement for an upfront cash payment of $250 million. The acquisition granted Roche rights to Good Therapeutics' conditionally active, PD-1-regulated IL-2 program and exclusive access to the platform technology for developing PD-1-regulated IL-2 receptor agonist therapies.
• Jun-2022: Bristol Myers Squibb acquired Turning Point Therapeutics in a definitive merger agreement, expanding its oncology franchise with a best-in-class precision oncology asset. Giovanni Caforio, M.D., Board Chair, and Chief Executive Officer at Bristol Myers Squibb stated that the transaction bolstered their growth profile through strategic business development.
• Oct-2021: Amgen, Inc. completed the acquisition of Teneobio, Inc., a biotechnology company that specializes in the development of human heavy chain antibodies, expanding its multispecific architectures and advancing the mission to develop transformative innovations for best-in-class products to serve patients.
• Aug-2020: Johnson & Johnson acquired Momenta Pharmaceuticals, a biotechnology company, specializes in the in the characterization and process engineering of complex molecules., for approximately $6.5 billion in an all-cash transaction, enhancing Janssen Pharmaceutical Companies' leadership in immune-mediated diseases. The deal included global rights to nipocalimab (M281), a potentially best-in-class anti-FcRn antibody, providing opportunities to address various autoimmune diseases with substantial unmet medical needs.

Scope of the Study

Market Segments Covered in the Report:

By Indication

• Breast Cancer
• Prostate Cancer
• Lung Cancer
• Stomach Cancer
• Colorectal Cancer
• Liver Cancer
• Esophagus Cancer
• Cervical Cancer
• Kidney Cancer
• Bladder Cancer
• Other Cancer

By Drug Class Type

• Targeted Therapy
• Immunotherapy (Biologic Therapy)
• Chemotherapy
• Hormonal Therapy

By Geography

• North America
  • US
  • Canada
  • Mexico
  • Rest of North America
• Europe
  • Germany
  • UK
  • France
  • Russia
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Singapore
  • Malaysia
  • Rest of Asia Pacific
• LAMEA
  • Brazil
  • Argentina
  • UAE
  • Saudi Arabia
  • South Africa
  • Nigeria
  • Rest of LAMEA

Key Market Players

List of Companies Profiled in the Report:

• AbbVie, Inc.
• Amgen, Inc.
• Astellas Pharma, Inc.
• AstraZeneca PLC
• Bristol Myers Squibb Company
• F.Hoffmann-La Roche Ltd.
• Johnson & Johnson
• Novartis AG
• Merck & Co., Inc.
• Pfizer Inc.

Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Global Oncology Drugs Market, by Indication
1.4.2 Global Oncology Drugs Market, by Drug Class Type
1.4.3 Global Oncology Drugs Market, by Geography
1.5 Methodology for the research

Chapter 2. Market at a Glance
2.1 Key Highlights

Chapter 3. Market Overview
3.1 Introduction
3.1.1 Overview
3.1.1.1 Market Composition and Scenario
3.2 Key Factors Impacting the Market
3.2.1 Market Drivers
3.2.2 Market Restraints

Chapter 4. Competition Analysis - Global
4.1 KBV Cardinal Matrix
4.2 Recent Industry Wide Strategic Developments
4.2.1 Partnerships, Collaborations and Agreements
4.2.2 Product Launches and Product Expansions
4.2.3 Acquisition and Mergers
4.3 Top Winning Strategies
4.3.1 Key Leading Strategies: Percentage Distribution (2019-2023)
4.3.2 Key Strategic Move: (Partnerships, Collaborations & Agreements : 2019, Mar – 2023, Nov) Leading Players
4.4 Porter’s Five Forces Analysis

Chapter 5. Global Oncology Drugs Market by Indication
5.1 Global Breast Cancer Market by Region
5.2 Global Prostate Cancer Market by Region
5.3 Global Lung Cancer Market by Region
5.4 Global Stomach Cancer Market by Region
5.5 Global Colorectal Cancer Market by Region
5.6 Global Liver Cancer Market by Region
5.7 Global Esophagus Cancer Market by Region
5.8 Global Cervical Cancer Market by Region
5.9 Global Kidney Cancer Market by Region
5.10. Global Bladder Cancer Market by Region
5.11 Global Other Cancer Market by Region

Chapter 6. Global Oncology Drugs Market by Drug Class Type
6.1 Global Targeted Therapy Market by Region
6.2 Global Immunotherapy (Biologic Therapy) Market by Region
6.3 Global Chemotherapy Market by Region
6.4 Global Hormonal Therapy Market by Region

Chapter 7. Global Oncology Drugs Market by Region
7.1 North America Oncology Drugs Market
7.1.1 North America Oncology Drugs Market by Indication
7.1.1.1 North America Breast Cancer Market by Country
7.1.1.2 North America Prostate Cancer Market by Country
7.1.1.3 North America Lung Cancer Market by Country
7.1.1.4 North America Stomach Cancer Market by Country
7.1.1.5 North America Colorectal Cancer Market by Country
7.1.1.6 North America Liver Cancer Market by Country
7.1.1.7 North America Esophagus Cancer Market by Country
7.1.1.8 North America Cervical Cancer Market by Country
7.1.1.9 North America Kidney Cancer Market by Country
7.1.1.10 North America Bladder Cancer Market by Country
7.1.1.11 North America Other Cancer Market by Country
7.1.2 North America Oncology Drugs Market by Drug Class Type
7.1.2.1 North America Targeted Therapy Market by Country
7.1.2.2 North America Immunotherapy (Biologic Therapy) Market by Country
7.1.2.3 North America Chemotherapy Market by Country
7.1.2.4 North America Hormonal Therapy Market by Country
7.1.3 North America Oncology Drugs Market by Country
7.1.3.1 US Oncology Drugs Market
7.1.3.1.1 US Oncology Drugs Market by Indication
7.1.3.1.2 US Oncology Drugs Market by Drug Class Type
7.1.3.2 Canada Oncology Drugs Market
7.1.3.2.1 Canada Oncology Drugs Market by Indication
7.1.3.2.2 Canada Oncology Drugs Market by Drug Class Type
7.1.3.3 Mexico Oncology Drugs Market
7.1.3.3.1 Mexico Oncology Drugs Market by Indication
7.1.3.3.2 Mexico Oncology Drugs Market by Drug Class Type
7.1.3.4 Rest of North America Oncology Drugs Market
7.1.3.4.1 Rest of North America Oncology Drugs Market by Indication
7.1.3.4.2 Rest of North America Oncology Drugs Market by Drug Class Type
7.2 Europe Oncology Drugs Market
7.2.1 Europe Oncology Drugs Market by Indication
7.2.1.1 Europe Breast Cancer Market by Country
7.2.1.2 Europe Prostate Cancer Market by Country
7.2.1.3 Europe Lung Cancer Market by Country
7.2.1.4 Europe Stomach Cancer Market by Country
7.2.1.5 Europe Colorectal Cancer Market by Country
7.2.1.6 Europe Liver Cancer Market by Country
7.2.1.7 Europe Esophagus Cancer Market by Country
7.2.1.8 Europe Cervical Cancer Market by Country
7.2.1.9 Europe Kidney Cancer Market by Country
7.2.1.10 Europe Bladder Cancer Market by Country
7.2.1.11 Europe Other Cancer Market by Country
7.2.2 Europe Oncology Drugs Market by Drug Class Type
7.2.2.1 Europe Targeted Therapy Market by Country
7.2.2.2 Europe Immunotherapy (Biologic Therapy) Market by Country
7.2.2.3 Europe Chemotherapy Market by Country
7.2.2.4 Europe Hormonal Therapy Market by Country
7.2.3 Europe Oncology Drugs Market by Country
7.2.3.1 Germany Oncology Drugs Market
7.2.3.1.1 Germany Oncology Drugs Market by Indication
7.2.3.1.2 Germany Oncology Drugs Market by Drug Class Type
7.2.3.2 UK Oncology Drugs Market
7.2.3.2.1 UK Oncology Drugs Market by Indication
7.2.3.2.2 UK Oncology Drugs Market by Drug Class Type
7.2.3.3 France Oncology Drugs Market
7.2.3.3.1 France Oncology Drugs Market by Indication
7.2.3.3.2 France Oncology Drugs Market by Drug Class Type
7.2.3.4 Russia Oncology Drugs Market
7.2.3.4.1 Russia Oncology Drugs Market by Indication
7.2.3.4.2 Russia Oncology Drugs Market by Drug Class Type
7.2.3.5 Spain Oncology Drugs Market
7.2.3.5.1 Spain Oncology Drugs Market by Indication
7.2.3.5.2 Spain Oncology Drugs Market by Drug Class Type
7.2.3.6 Italy Oncology Drugs Market
7.2.3.6.1 Italy Oncology Drugs Market by Indication
7.2.3.6.2 Italy Oncology Drugs Market by Drug Class Type
7.2.3.7 Rest of Europe Oncology Drugs Market
7.2.3.7.1 Rest of Europe Oncology Drugs Market by Indication
7.2.3.7.2 Rest of Europe Oncology Drugs Market by Drug Class Type
7.3 Asia Pacific Oncology Drugs Market
7.3.1 Asia Pacific Oncology Drugs Market by Indication
7.3.1.1 Asia Pacific Breast Cancer Market by Country
7.3.1.2 Asia Pacific Prostate Cancer Market by Country
7.3.1.3 Asia Pacific Lung Cancer Market by Country
7.3.1.4 Asia Pacific Stomach Cancer Market by Country
7.3.1.5 Asia Pacific Colorectal Cancer Market by Country
7.3.1.6 Asia Pacific Liver Cancer Market by Country
7.3.1.7 Asia Pacific Esophagus Cancer Market by Country
7.3.1.8 Asia Pacific Cervical Cancer Market by Country
7.3.1.9 Asia Pacific Kidney Cancer Market by Country
7.3.1.10 Asia Pacific Bladder Cancer Market by Country
7.3.1.11 Asia Pacific Other Cancer Market by Country
7.3.2 Asia Pacific Oncology Drugs Market by Drug Class Type
7.3.2.1 Asia Pacific Targeted Therapy Market by Country
7.3.2.2 Asia Pacific Immunotherapy (Biologic Therapy) Market by Country
7.3.2.3 Asia Pacific Chemotherapy Market by Country
7.3.2.4 Asia Pacific Hormonal Therapy Market by Country
7.3.3 Asia Pacific Oncology Drugs Market by Country
7.3.3.1 China Oncology Drugs Market
7.3.3.1.1 China Oncology Drugs Market by Indication
7.3.3.1.2 China Oncology Drugs Market by Drug Class Type
7.3.3.2 Japan Oncology Drugs Market
7.3.3.2.1 Japan Oncology Drugs Market by Indication
7.3.3.2.2 Japan Oncology Drugs Market by Drug Class Type
7.3.3.3 India Oncology Drugs Market
7.3.3.3.1 India Oncology Drugs Market by Indication
7.3.3.3.2 India Oncology Drugs Market by Drug Class Type
7.3.3.4 South Korea Oncology Drugs Market
7.3.3.4.1 South Korea Oncology Drugs Market by Indication
7.3.3.4.2 South Korea Oncology Drugs Market by Drug Class Type
7.3.3.5 Singapore Oncology Drugs Market
7.3.3.5.1 Singapore Oncology Drugs Market by Indication
7.3.3.5.2 Singapore Oncology Drugs Market by Drug Class Type
7.3.3.6 Malaysia Oncology Drugs Market
7.3.3.6.1 Malaysia Oncology Drugs Market by Indication
7.3.3.6.2 Malaysia Oncology Drugs Market by Drug Class Type
7.3.3.7 Rest of Asia Pacific Oncology Drugs Market
7.3.3.7.1 Rest of Asia Pacific Oncology Drugs Market by Indication
7.3.3.7.2 Rest of Asia Pacific Oncology Drugs Market by Drug Class Type
7.4 LAMEA Oncology Drugs Market
7.4.1 LAMEA Oncology Drugs Market by Indication
7.4.1.1 LAMEA Breast Cancer Market by Country
7.4.1.2 LAMEA Prostate Cancer Market by Country
7.4.1.3 LAMEA Lung Cancer Market by Country
7.4.1.4 LAMEA Stomach Cancer Market by Country
7.4.1.5 LAMEA Colorectal Cancer Market by Country
7.4.1.6 LAMEA Liver Cancer Market by Country
7.4.1.7 LAMEA Esophagus Cancer Market by Country
7.4.1.8 LAMEA Cervical Cancer Market by Country
7.4.1.9 LAMEA Kidney Cancer Market by Country
7.4.1.10 LAMEA Bladder Cancer Market by Country
7.4.1.11 LAMEA Other Cancer Market by Country
7.4.2 LAMEA Oncology Drugs Market by Drug Class Type
7.4.2.1 LAMEA Targeted Therapy Market by Country
7.4.2.2 LAMEA Immunotherapy (Biologic Therapy) Market by Country
7.4.2.3 LAMEA Chemotherapy Market by Country
7.4.2.4 LAMEA Hormonal Therapy Market by Country
7.4.3 LAMEA Oncology Drugs Market by Country
7.4.3.1 Brazil Oncology Drugs Market
7.4.3.1.1 Brazil Oncology Drugs Market by Indication
7.4.3.1.2 Brazil Oncology Drugs Market by Drug Class Type
7.4.3.2 Argentina Oncology Drugs Market
7.4.3.2.1 Argentina Oncology Drugs Market by Indication
7.4.3.2.2 Argentina Oncology Drugs Market by Drug Class Type
7.4.3.3 UAE Oncology Drugs Market
7.4.3.3.1 UAE Oncology Drugs Market by Indication
7.4.3.3.2 UAE Oncology Drugs Market by Drug Class Type
7.4.3.4 Saudi Arabia Oncology Drugs Market
7.4.3.4.1 Saudi Arabia Oncology Drugs Market by Indication
7.4.3.4.2 Saudi Arabia Oncology Drugs Market by Drug Class Type
7.4.3.5 South Africa Oncology Drugs Market
7.4.3.5.1 South Africa Oncology Drugs Market by Indication
7.4.3.5.2 South Africa Oncology Drugs Market by Drug Class Type
7.4.3.6 Nigeria Oncology Drugs Market
7.4.3.6.1 Nigeria Oncology Drugs Market by Indication
7.4.3.6.2 Nigeria Oncology Drugs Market by Drug Class Type
7.4.3.7 Rest of LAMEA Oncology Drugs Market
7.4.3.7.1 Rest of LAMEA Oncology Drugs Market by Indication
7.4.3.7.2 Rest of LAMEA Oncology Drugs Market by Drug Class Type

Chapter 8. Company Profiles
8.1 AbbVie, Inc.
8.1.1 Company Overview
8.1.2 Financial Analysis
8.1.3 Regional Analysis
8.1.4 Research & Development Expense
8.1.5 Recent strategies and developments:
8.1.5.1 Partnerships, Collaborations, and Agreements:
8.1.5.2 Acquisition and Mergers:
8.1.6 SWOT Analysis
8.2 Amgen, Inc.
8.2.1 Company Overview
8.2.2 Financial Analysis
8.2.3 Regional Analysis
8.2.4 Research & Development Expenses
8.2.5 Recent strategies and developments:
8.2.5.1 Acquisition and Mergers:
8.2.6 SWOT Analysis
8.3 Astellas Pharma, Inc.
8.3.1 Company Overview
8.3.2 Financial Analysis
8.3.3 Regional Analysis
8.3.4 Research & Development Expense
8.3.5 Recent strategies and developments:
8.3.5.1 Partnerships, Collaborations, and Agreements:
8.3.5.2 Acquisition and Mergers:
8.3.6 SWOT Analysis
8.4 AstraZeneca PLC
8.4.1 Company Overview
8.4.2 Financial Analysis
8.4.3 Regional Analysis
8.4.4 Research & Development Expenses
8.4.5 Recent strategies and developments:
8.4.5.1 Partnerships, Collaborations, and Agreements:
8.4.5.2 Product Launches and Product Expansions:
8.4.6 SWOT Analysis
8.5 Bristol Myers Squibb Company
8.5.1 Company Overview
8.5.2 Financial Analysis
8.5.3 Regional Analysis
8.5.4 Research & Development Expenses
8.5.5 Recent strategies and developments:
8.5.5.1 Partnerships, Collaborations, and Agreements:
8.5.5.2 Product Launches and Product Expansions:
8.5.5.3 Acquisition and Mergers:
8.5.6 SWOT Analysis
8.6 F. Hoffmann-La Roche Ltd.
8.6.1 Company Overview
8.6.2 Financial Analysis
8.6.3 Segmental and Regional Analysis
8.6.4 Research & Development Expense
8.6.5 Recent strategies and developments:
8.6.5.1 Partnerships, Collaborations, and Agreements:
8.6.5.2 Product Launches and Product Expansions:
8.6.5.3 Acquisition and Mergers:
8.6.6 SWOT Analysis
8.7 Johnson & Johnson
8.7.1 Company Overview
8.7.2 Financial Analysis
8.7.3 Segmental & Regional Analysis
8.7.4 Research & Development Expenses
8.7.5 Recent strategies and developments:
8.7.5.1 Partnerships, Collaborations, and Agreements:
8.7.5.2 Acquisition and Mergers:
8.7.6 SWOT Analysis
8.8 Novartis AG
8.8.1 Company Overview
8.8.2 Financial Analysis
8.8.3 Segmental and Regional Analysis
8.8.4 Research & Development Expense
8.8.5 Recent strategies and developments:
8.8.5.1 Partnerships, Collaborations, and Agreements:
8.8.6 SWOT Analysis
8.9 Merck & Co., Inc.
8.9.1 Company Overview
8.9.2 Financial Analysis
8.9.3 Segmental and Regional Analysis
8.9.4 Research & Development Expenses
8.9.5 Recent strategies and developments:
8.9.5.1 Partnerships, Collaborations, and Agreements:
8.9.5.2 Acquisition and Mergers:
8.9.6 SWOT Analysis
8.10. Pfizer, Inc.
8.10.1 Company Overview
8.10.2 Financial Analysis
8.10.3 Regional & Segmental Analysis
8.10.4 Research & Development Expense
8.10.5 Recent strategies and developments:
8.10.5.1 Partnerships, Collaborations, and Agreements:
8.10.6 SWOT Analysis

Chapter 9. Winning Imperatives of Oncology Drugs Market

TABLE 1 Global Oncology Drugs Market, 2019 - 2022, USD Million
TABLE 2 Global Oncology Drugs Market, 2023 - 2030, USD Million
TABLE 3 Partnerships, Collaborations and Agreements– Oncology Drugs Market
TABLE 4 Product Launches And Product Expansions– Oncology Drugs Market
TABLE 5 Acquisition and Mergers– Oncology Drugs Market
TABLE 6 Global Oncology Drugs Market by Indication, 2019 - 2022, USD Million
TABLE 7 Global Oncology Drugs Market by Indication, 2023 - 2030, USD Million
TABLE 8 Global Breast Cancer Market by Region, 2019 - 2022, USD Million
TABLE 9 Global Breast Cancer Market by Region, 2023 - 2030, USD Million
TABLE 10 Global Prostate Cancer Market by Region, 2019 - 2022, USD Million
TABLE 11 Global Prostate Cancer Market by Region, 2023 - 2030, USD Million
TABLE 12 Global Lung Cancer Market by Region, 2019 - 2022, USD Million
TABLE 13 Global Lung Cancer Market by Region, 2023 - 2030, USD Million
TABLE 14 Global Stomach Cancer Market by Region, 2019 - 2022, USD Million
TABLE 15 Global Stomach Cancer Market by Region, 2023 - 2030, USD Million
TABLE 16 Global Colorectal Cancer Market by Region, 2019 - 2022, USD Million
TABLE 17 Global Colorectal Cancer Market by Region, 2023 - 2030, USD Million
TABLE 18 Global Liver Cancer Market by Region, 2019 - 2022, USD Million
TABLE 19 Global Liver Cancer Market by Region, 2023 - 2030, USD Million
TABLE 20 Global Esophagus Cancer Market by Region, 2019 - 2022, USD Million
TABLE 21 Global Esophagus Cancer Market by Region, 2023 - 2030, USD Million
TABLE 22 Global Cervical Cancer Market by Region, 2019 - 2022, USD Million
TABLE 23 Global Cervical Cancer Market by Region, 2023 - 2030, USD Million
TABLE 24 Global Kidney Cancer Market by Region, 2019 - 2022, USD Million
TABLE 25 Global Kidney Cancer Market by Region, 2023 - 2030, USD Million
TABLE 26 Global Bladder Cancer Market by Region, 2019 - 2022, USD Million
TABLE 27 Global Bladder Cancer Market by Region, 2023 - 2030, USD Million
TABLE 28 Global Other Cancer Market by Region, 2019 - 2022, USD Million
TABLE 29 Global Other Cancer Market by Region, 2023 - 2030, USD Million
TABLE 30 Global Oncology Drugs Market by Drug Class Type, 2019 - 2022, USD Million
TABLE 31 Global Oncology Drugs Market by Drug Class Type, 2023 - 2030, USD Million
TABLE 32 Global Targeted Therapy Market by Region, 2019 - 2022, USD Million
TABLE 33 Global Targeted Therapy Market by Region, 2023 - 2030, USD Million
TABLE 34 Global Immunotherapy (Biologic Therapy) Market by Region, 2019 - 2022, USD Million
TABLE 35 Global Immunotherapy (Biologic Therapy) Market by Region, 2023 - 2030, USD Million
TABLE 36 Global Chemotherapy Market by Region, 2019 - 2022, USD Million
TABLE 37 Global Chemotherapy Market by Region, 2023 - 2030, USD Million
TABLE 38 Global Hormonal Therapy Market by Region, 2019 - 2022, USD Million
TABLE 39 Global Hormonal Therapy Market by Region, 2023 - 2030, USD Million
TABLE 40 Global Oncology Drugs Market by Region, 2019 - 2022, USD Million
TABLE 41 Global Oncology Drugs Market by Region, 2023 - 2030, USD Million
TABLE 42 North America Oncology Drugs Market, 2019 - 2022, USD Million
TABLE 43 North America Oncology Drugs Market, 2023 - 2030, USD Million
TABLE 44 North America Oncology Drugs Market by Indication, 2019 - 2022, USD Million
TABLE 45 North America Oncology Drugs Market by Indication, 2023 - 2030, USD Million
TABLE 46 North America Breast Cancer Market by Country, 2019 - 2022, USD Million
TABLE 47 North America Breast Cancer Market by Country, 2023 - 2030, USD Million
TABLE 48 North America Prostate Cancer Market by Country, 2019 - 2022, USD Million
TABLE 49 North America Prostate Cancer Market by Country, 2023 - 2030, USD Million
TABLE 50 North America Lung Cancer Market by Country, 2019 - 2022, USD Million
TABLE 51 North America Lung Cancer Market by Country, 2023 - 2030, USD Million
TABLE 52 North America Stomach Cancer Market by Country, 2019 - 2022, USD Million
TABLE 53 North America Stomach Cancer Market by Country, 2023 - 2030, USD Million
TABLE 54 North America Colorectal Cancer Market by Country, 2019 - 2022, USD Million
TABLE 55 North America Colorectal Cancer Market by Country, 2023 - 2030, USD Million
TABLE 56 North America Liver Cancer Market by Country, 2019 - 2022, USD Million
TABLE 57 North America Liver Cancer Market by Country, 2023 - 2030, USD Million
TABLE 58 North America Esophagus Cancer Market by Country, 2019 - 2022, USD Million
TABLE 59 North America Esophagus Cancer Market by Country, 2023 - 2030, USD Million
TABLE 60 North America Cervical Cancer Market by Country, 2019 - 2022, USD Million
TABLE 61 North America Cervical Cancer Market by Country, 2023 - 2030, USD Million
TABLE 62 North America Kidney Cancer Market by Country, 2019 - 2022, USD Million
TABLE 63 North America Kidney Cancer Market by Country, 2023 - 2030, USD Million
TABLE 64 North America Bladder Cancer Market by Country, 2019 - 2022, USD Million
TABLE 65 North America Bladder Cancer Market by Country, 2023 - 2030, USD Million
TABLE 66 North America Other Cancer Market by Country, 2019 - 2022, USD Million
TABLE 67 North America Other Cancer Market by Country, 2023 - 2030, USD Million
TABLE 68 North America Oncology Drugs Market by Drug Class Type, 2019 - 2022, USD Million
TABLE 69 North America Oncology Drugs Market by Drug Class Type, 2023 - 2030, USD Million
TABLE 70 North America Targeted Therapy Market by Country, 2019 - 2022, USD Million
TABLE 71 North America Targeted Therapy Market by Country, 2023 - 2030, USD Million
TABLE 72 North America Immunotherapy (Biologic Therapy) Market by Country, 2019 - 2022, USD Million
TABLE 73 North America Immunotherapy (Biologic Therapy) Market by Country, 2023 - 2030, USD Million
TABLE 74 North America Chemotherapy Market by Country, 2019 - 2022, USD Million
TABLE 75 North America Chemotherapy Market by Country, 2023 - 2030, USD Million
TABLE 76 North America Hormonal Therapy Market by Country, 2019 - 2022, USD Million
TABLE 77 North America Hormonal Therapy Market by Country, 2023 - 2030, USD Million
TABLE 78 North America Oncology Drugs Market by Country, 2019 - 2022, USD Million
TABLE 79 North America Oncology Drugs Market by Country, 2023 - 2030, USD Million
TABLE 80 US Oncology Drugs Market, 2019 - 2022, USD Million
TABLE 81 US Oncology Drugs Market, 2023 - 2030, USD Million
TABLE 82 US Oncology Drugs Market by Indication, 2019 - 2022, USD Million
TABLE 83 US Oncology Drugs Market by Indication, 2023 - 2030, USD Million
TABLE 84 US Oncology Drugs Market by Drug Class Type, 2019 - 2022, USD Million
TABLE 85 US Oncology Drugs Market by Drug Class Type, 2023 - 2030, USD Million
TABLE 86 Canada Oncology Drugs Market, 2019 - 2022, USD Million
TABLE 87 Canada Oncology Drugs Market, 2023 - 2030, USD Million
TABLE 88 Canada Oncology Drugs Market by Indication, 2019 - 2022, USD Million
TABLE 89 Canada Oncology Drugs Market by Indication, 2023 - 2030, USD Million
TABLE 90 Canada Oncology Drugs Market by Drug Class Type, 2019 - 2022, USD Million
TABLE 91 Canada Oncology Drugs Market by Drug Class Type, 2023 - 2030, USD Million
TABLE 92 Mexico Oncology Drugs Market, 2019 - 2022, USD Million
TABLE 93 Mexico Oncology Drugs Market, 2023 - 2030, USD Million
TABLE 94 Mexico Oncology Drugs Market by Indication, 2019 - 2022, USD Million
TABLE 95 Mexico Oncology Drugs Market by Indication, 2023 - 2030, USD Million
TABLE 96 Mexico Oncology Drugs Market by Drug Class Type, 2019 - 2022, USD Million
TABLE 97 Mexico Oncology Drugs Market by Drug Class Type, 2023 - 2030, USD Million
TABLE 98 Rest of North America Oncology Drugs Market, 2019 - 2022, USD Million
TABLE 99 Rest of North America Oncology Drugs Market, 2023 - 2030, USD Million
TABLE 100 Rest of North America Oncology Drugs Market by Indication, 2019 - 2022, USD Million
TABLE 101 Rest of North America Oncology Drugs Market by Indication, 2023 - 2030, USD Million
TABLE 102 Rest of North America Oncology Drugs Market by Drug Class Type, 2019 - 2022, USD Million
TABLE 103 Rest of North America Oncology Drugs Market by Drug Class Type, 2023 - 2030, USD Million
TABLE 104 Europe Oncology Drugs Market, 2019 - 2022, USD Million
TABLE 105 Europe Oncology Drugs Market, 2023 - 2030, USD Million
TABLE 106 Europe Oncology Drugs Market by Indication, 2019 - 2022, USD Million
TABLE 107 Europe Oncology Drugs Market by Indication, 2023 - 2030, USD Million
TABLE 108 Europe Breast Cancer Market by Country, 2019 - 2022, USD Million
TABLE 109 Europe Breast Cancer Market by Country, 2023 - 2030, USD Million
TABLE 110 Europe Prostate Cancer Market by Country, 2019 - 2022, USD Million
TABLE 111 Europe Prostate Cancer Market by Country, 2023 - 2030, USD Million
TABLE 112 Europe Lung Cancer Market by Country, 2019 - 2022, USD Million
TABLE 113 Europe Lung Cancer Market by Country, 2023 - 2030, USD Million
TABLE 114 Europe Stomach Cancer Market by Country, 2019 - 2022, USD Million
TABLE 115 Europe Stomach Cancer Market by Country, 2023 - 2030, USD Million
TABLE 116 Europe Colorectal Cancer Market by Country, 2019 - 2022, USD Million
TABLE 117 Europe Colorectal Cancer Market by Country, 2023 - 2030, USD Million
TABLE 118 Europe Liver Cancer Market by Country, 2019 - 2022, USD Million
TABLE 119 Europe Liver Cancer Market by Country, 2023 - 2030, USD Million
TABLE 120 Europe Esophagus Cancer Market by Country, 2019 - 2022, USD Million
TABLE 121 Europe Esophagus Cancer Market by Country, 2023 - 2030, USD Million
TABLE 122 Europe Cervical Cancer Market by Country, 2019 - 2022, USD Million
TABLE 123 Europe Cervical Cancer Market by Country, 2023 - 2030, USD Million
TABLE 124 Europe Kidney Cancer Market by Country, 2019 - 2022, USD Million
TABLE 125 Europe Kidney Cancer Market by Country, 2023 - 2030, USD Million
TABLE 126 Europe Bladder Cancer Market by Country, 2019 - 2022, USD Million
TABLE 127 Europe Bladder Cancer Market by Country, 2023 - 2030, USD Million
TABLE 128 Europe Other Cancer Market by Country, 2019 - 2022, USD Million
TABLE 129 Europe Other Cancer Market by Country, 2023 - 2030, USD Million
TABLE 130 Europe Oncology Drugs Market by Drug Class Type, 2019 - 2022, USD Million
TABLE 131 Europe Oncology Drugs Market by Drug Class Type, 2023 - 2030, USD Million
TABLE 132 Europe Targeted Therapy Market by Country, 2019 - 2022, USD Million
TABLE 133 Europe Targeted Therapy Market by Country, 2023 - 2030, USD Million
TABLE 134 Europe Immunotherapy (Biologic Therapy) Market by Country, 2019 - 2022, USD Million
TABLE 135 Europe Immunotherapy (Biologic Therapy) Market by Country, 2023 - 2030, USD Million
TABLE 136 Europe Chemotherapy Market by Country, 2019 - 2022, USD Million
TABLE 137 Europe Chemotherapy Market by Country, 2023 - 2030, USD Million
TABLE 138 Europe Hormonal Therapy Market by Country, 2019 - 2022, USD Million
TABLE 139 Europe Hormonal Therapy Market by Country, 2023 - 2030, USD Million
TABLE 140 Europe Oncology Drugs Market by Country, 2019 - 2022, USD Million
TABLE 141 Europe Oncology Drugs Market by Country, 2023 - 2030, USD Million
TABLE 142 Germany Oncology Drugs Market, 2019 - 2022, USD Million
TABLE 143 Germany Oncology Drugs Market, 2023 - 2030, USD Million
TABLE 144 Germany Oncology Drugs Market by Indication, 2019 - 2022, USD Million
TABLE 145 Germany Oncology Drugs Market by Indication, 2023 - 2030, USD Million
TABLE 146 Germany Oncology Drugs Market by Drug Class Type, 2019 - 2022, USD Million
TABLE 147 Germany Oncology Drugs Market by Drug Class Type, 2023 - 2030, USD Million
TABLE 148 UK Oncology Drugs Market, 2019 - 2022, USD Million
TABLE 149 UK Oncology Drugs Market, 2023 - 2030, USD Million
TABLE 150 UK Oncology Drugs Market by Indication, 2019 - 2022, USD Million
TABLE 151 UK Oncology Drugs Market by Indication, 2023 - 2030, USD Million
TABLE 152 UK Oncology Drugs Market by Drug Class Type, 2019 - 2022, USD Million
TABLE 153 UK Oncology Drugs Market by Drug Class Type, 2023 - 2030, USD Million
TABLE 154 France Oncology Drugs Market, 2019 - 2022, USD Million
TABLE 155 France Oncology Drugs Market, 2023 - 2030, USD Million
TABLE 156 France Oncology Drugs Market by Indication, 2019 - 2022, USD Million
TABLE 157 France Oncology Drugs Market by Indication, 2023 - 2030, USD Million
TABLE 158 France Oncology Drugs Market by Drug Class Type, 2019 - 2022, USD Million
TABLE 159 France Oncology Drugs Market by Drug Class Type, 2023 - 2030, USD Million
TABLE 160 Russia Oncology Drugs Market, 2019 - 2022, USD Million
TABLE 161 Russia Oncology Drugs Market, 2023 - 2030, USD Million
TABLE 162 Russia Oncology Drugs Market by Indication, 2019 - 2022, USD Million
TABLE 163 Russia Oncology Drugs Market by Indication, 2023 - 2030, USD Million
TABLE 164 Russia Oncology Drugs Market by Drug Class Type, 2019 - 2022, USD Million
TABLE 165 Russia Oncology Drugs Market by Drug Class Type, 2023 - 2030, USD Million
TABLE 166 Spain Oncology Drugs Market, 2019 - 2022, USD Million
TABLE 167 Spain Oncology Drugs Market, 2023 - 2030, USD Million
TABLE 168 Spain Oncology Drugs Market by Indication, 2019 - 2022, USD Million
TABLE 169 Spain Oncology Drugs Market by Indication, 2023 - 2030, USD Million
TABLE 170 Spain Oncology Drugs Market by Drug Class Type, 2019 - 2022, USD Million
TABLE 171 Spain Oncology Drugs Market by Drug Class Type, 2023 - 2030, USD Million
TABLE 172 Italy Oncology Drugs Market, 2019 - 2022, USD Million
TABLE 173 Italy Oncology Drugs Market, 2023 - 2030, USD Million
TABLE 174 Italy Oncology Drugs Market by Indication, 2019 - 2022, USD Million
TABLE 175 Italy Oncology Drugs Market by Indication, 2023 - 2030, USD Million
TABLE 176 Italy Oncology Drugs Market by Drug Class Type, 2019 - 2022, USD Million
TABLE 177 Italy Oncology Drugs Market by Drug Class Type, 2023 - 2030, USD Million
TABLE 178 Rest of Europe Oncology Drugs Market, 2019 - 2022, USD Million
TABLE 179 Rest of Europe Oncology Drugs Market, 2023 - 2030, USD Million
TABLE 180 Rest of Europe Oncology Drugs Market by Indication, 2019 - 2022, USD Million
TABLE 181 Rest of Europe Oncology Drugs Market by Indication, 2023 - 2030, USD Million
TABLE 182 Rest of Europe Oncology Drugs Market by Drug Class Type, 2019 - 2022, USD Million
TABLE 183 Rest of Europe Oncology Drugs Market by Drug Class Type, 2023 - 2030, USD Million
TABLE 184 Asia Pacific Oncology Drugs Market, 2019 - 2022, USD Million
TABLE 185 Asia Pacific Oncology Drugs Market, 2023 - 2030, USD Million
TABLE 186 Asia Pacific Oncology Drugs Market by Indication, 2019 - 2022, USD Million
TABLE 187 Asia Pacific Oncology Drugs Market by Indication, 2023 - 2030, USD Million
TABLE 188 Asia Pacific Breast Cancer Market by Country, 2019 - 2022, USD Million
TABLE 189 Asia Pacific Breast Cancer Market by Country, 2023 - 2030, USD Million
TABLE 190 Asia Pacific Prostate Cancer Market by Country, 2019 - 2022, USD Million
TABLE 191 Asia Pacific Prostate Cancer Market by Country, 2023 - 2030, USD Million
TABLE 192 Asia Pacific Lung Cancer Market by Country, 2019 - 2022, USD Million
TABLE 193 Asia Pacific Lung Cancer Market by Country, 2023 - 2030, USD Million
TABLE 194 Asia Pacific Stomach Cancer Market by Country, 2019 - 2022, USD Million
TABLE 195 Asia Pacific Stomach Cancer Market by Country, 2023 - 2030, USD Million
TABLE 196 Asia Pacific Colorectal Cancer Market by Country, 2019 - 2022, USD Million
TABLE 197 Asia Pacific Colorectal Cancer Market by Country, 2023 - 2030, USD Million
TABLE 198 Asia Pacific Liver Cancer Market by Country, 2019 - 2022, USD Million
TABLE 199 Asia Pacific Liver Cancer Market by Country, 2023 - 2030, USD Million
TABLE 200 Asia Pacific Esophagus Cancer Market by Country, 2019 - 2022, USD Million
TABLE 201 Asia Pacific Esophagus Cancer Market by Country, 2023 - 2030, USD Million
TABLE 202 Asia Pacific Cervical Cancer Market by Country, 2019 - 2022, USD Million
TABLE 203 Asia Pacific Cervical Cancer Market by Country, 2023 - 2030, USD Million
TABLE 204 Asia Pacific Kidney Cancer Market by Country, 2019 - 2022, USD Million
TABLE 205 Asia Pacific Kidney Cancer Market by Country, 2023 - 2030, USD Million
TABLE 206 Asia Pacific Bladder Cancer Market by Country, 2019 - 2022, USD Million
TABLE 207 Asia Pacific Bladder Cancer Market by Country, 2023 - 2030, USD Million
TABLE 208 Asia Pacific Other Cancer Market by Country, 2019 - 2022, USD Million
TABLE 209 Asia Pacific Other Cancer Market by Country, 2023 - 2030, USD Million
TABLE 210 Asia Pacific Oncology Drugs Market by Drug Class Type, 2019 - 2022, USD Million
TABLE 211 Asia Pacific Oncology Drugs Market by Drug Class Type, 2023 - 2030, USD Million
TABLE 212 Asia Pacific Targeted Therapy Market by Country, 2019 - 2022, USD Million
TABLE 213 Asia Pacific Targeted Therapy Market by Country, 2023 - 2030, USD Million
TABLE 214 Asia Pacific Immunotherapy (Biologic Therapy) Market by Country, 2019 - 2022, USD Million
TABLE 215 Asia Pacific Immunotherapy (Biologic Therapy) Market by Country, 2023 - 2030, USD Million
TABLE 216 Asia Pacific Chemotherapy Market by Country, 2019 - 2022, USD Million
TABLE 217 Asia Pacific Chemotherapy Market by Country, 2023 - 2030, USD Million
TABLE 218 Asia Pacific Hormonal Therapy Market by Country, 2019 - 2022, USD Million
TABLE 219 Asia Pacific Hormonal Therapy Market by Country, 2023 - 2030, USD Million
TABLE 220 Asia Pacific Oncology Drugs Market by Country, 2019 - 2022, USD Million
TABLE 221 Asia Pacific Oncology Drugs Market by Country, 2023 - 2030, USD Million
TABLE 222 China Oncology Drugs Market, 2019 - 2022, USD Million
TABLE 223 China Oncology Drugs Market, 2023 - 2030, USD Million
TABLE 224 China Oncology Drugs Market by Indication, 2019 - 2022, USD Million
TABLE 225 China Oncology Drugs Market by Indication, 2023 - 2030, USD Million
TABLE 226 China Oncology Drugs Market by Drug Class Type, 2019 - 2022, USD Million
TABLE 227 China Oncology Drugs Market by Drug Class Type, 2023 - 2030, USD Million
TABLE 228 Japan Oncology Drugs Market, 2019 - 2022, USD Million
TABLE 229 Japan Oncology Drugs Market, 2023 - 2030, USD Million
TABLE 230 Japan Oncology Drugs Market by Indication, 2019 - 2022, USD Million
TABLE 231 Japan Oncology Drugs Market by Indication, 2023 - 2030, USD Million
TABLE 232 Japan Oncology Drugs Market by Drug Class Type, 2019 - 2022, USD Million
TABLE 233 Japan Oncology Drugs Market by Drug Class Type, 2023 - 2030, USD Million
TABLE 234 India Oncology Drugs Market, 2019 - 2022, USD Million
TABLE 235 India Oncology Drugs Market, 2023 - 2030, USD Million
TABLE 236 India Oncology Drugs Market by Indication, 2019 - 2022, USD Million
TABLE 237 India Oncology Drugs Market by Indication, 2023 - 2030, USD Million
TABLE 238 India Oncology Drugs Market by Drug Class Type, 2019 - 2022, USD Million
TABLE 239 India Oncology Drugs Market by Drug Class Type, 2023 - 2030, USD Million
TABLE 240 South Korea Oncology Drugs Market, 2019 - 2022, USD Million
TABLE 241 South Korea Oncology Drugs Market, 2023 - 2030, USD Million
TABLE 242 South Korea Oncology Drugs Market by Indication, 2019 - 2022, USD Million
TABLE 243 South Korea Oncology Drugs Market by Indication, 2023 - 2030, USD Million
TABLE 244 South Korea Oncology Drugs Market by Drug Class Type, 2019 - 2022, USD Million
TABLE 245 South Korea Oncology Drugs Market by Drug Class Type, 2023 - 2030, USD Million
TABLE 246 Singapore Oncology Drugs Market, 2019 - 2022, USD Million
TABLE 247 Singapore Oncology Drugs Market, 2023 - 2030, USD Million
TABLE 248 Singapore Oncology Drugs Market by Indication, 2019 - 2022, USD Million
TABLE 249 Singapore Oncology Drugs Market by Indication, 2023 - 2030, USD Million
TABLE 250 Singapore Oncology Drugs Market by Drug Class Type, 2019 - 2022, USD Million
TABLE 251 Singapore Oncology Drugs Market by Drug Class Type, 2023 - 2030, USD Million
TABLE 252 Malaysia Oncology Drugs Market, 2019 - 2022, USD Million
TABLE 253 Malaysia Oncology Drugs Market, 2023 - 2030, USD Million
TABLE 254 Malaysia Oncology Drugs Market by Indication, 2019 - 2022, USD Million
TABLE 255 Malaysia Oncology Drugs Market by Indication, 2023 - 2030, USD Million
TABLE 256 Malaysia Oncology Drugs Market by Drug Class Type, 2019 - 2022, USD Million
TABLE 257 Malaysia Oncology Drugs Market by Drug Class Type, 2023 - 2030, USD Million
TABLE 258 Rest of Asia Pacific Oncology Drugs Market, 2019 - 2022, USD Million
TABLE 259 Rest of Asia Pacific Oncology Drugs Market, 2023 - 2030, USD Million
TABLE 260 Rest of Asia Pacific Oncology Drugs Market by Indication, 2019 - 2022, USD Million
TABLE 261 Rest of Asia Pacific Oncology Drugs Market by Indication, 2023 - 2030, USD Million
TABLE 262 Rest of Asia Pacific Oncology Drugs Market by Drug Class Type, 2019 - 2022, USD Million
TABLE 263 Rest of Asia Pacific Oncology Drugs Market by Drug Class Type, 2023 - 2030, USD Million
TABLE 264 LAMEA Oncology Drugs Market, 2019 - 2022, USD Million
TABLE 265 LAMEA Oncology Drugs Market, 2023 - 2030, USD Million
TABLE 266 LAMEA Oncology Drugs Market by Indication, 2019 - 2022, USD Million
TABLE 267 LAMEA Oncology Drugs Market by Indication, 2023 - 2030, USD Million
TABLE 268 LAMEA Breast Cancer Market by Country, 2019 - 2022, USD Million
TABLE 269 LAMEA Breast Cancer Market by Country, 2023 - 2030, USD Million
TABLE 270 LAMEA Prostate Cancer Market by Country, 2019 - 2022, USD Million
TABLE 271 LAMEA Prostate Cancer Market by Country, 2023 - 2030, USD Million
TABLE 272 LAMEA Lung Cancer Market by Country, 2019 - 2022, USD Million
TABLE 273 LAMEA Lung Cancer Market by Country, 2023 - 2030, USD Million
TABLE 274 LAMEA Stomach Cancer Market by Country, 2019 - 2022, USD Million
TABLE 275 LAMEA Stomach Cancer Market by Country, 2023 - 2030, USD Million
TABLE 276 LAMEA Colorectal Cancer Market by Country, 2019 - 2022, USD Million
TABLE 277 LAMEA Colorectal Cancer Market by Country, 2023 - 2030, USD Million
TABLE 278 LAMEA Liver Cancer Market by Country, 2019 - 2022, USD Million
TABLE 279 LAMEA Liver Cancer Market by Country, 2023 - 2030, USD Million
TABLE 280 LAMEA Esophagus Cancer Market by Country, 2019 - 2022, USD Million
TABLE 281 LAMEA Esophagus Cancer Market by Country, 2023 - 2030, USD Million
TABLE 282 LAMEA Cervical Cancer Market by Country, 2019 - 2022, USD Million
TABLE 283 LAMEA Cervical Cancer Market by Country, 2023 - 2030, USD Million
TABLE 284 LAMEA Kidney Cancer Market by Country, 2019 - 2022, USD Million
TABLE 285 LAMEA Kidney Cancer Market by Country, 2023 - 2030, USD Million
TABLE 286 LAMEA Bladder Cancer Market by Country, 2019 - 2022, USD Million
TABLE 287 LAMEA Bladder Cancer Market by Country, 2023 - 2030, USD Million
TABLE 288 LAMEA Other Cancer Market by Country, 2019 - 2022, USD Million
TABLE 289 LAMEA Other Cancer Market by Country, 2023 - 2030, USD Million
TABLE 290 LAMEA Oncology Drugs Market by Drug Class Type, 2019 - 2022, USD Million
TABLE 291 LAMEA Oncology Drugs Market by Drug Class Type, 2023 - 2030, USD Million
TABLE 292 LAMEA Targeted Therapy Market by Country, 2019 - 2022, USD Million
TABLE 293 LAMEA Targeted Therapy Market by Country, 2023 - 2030, USD Million
TABLE 294 LAMEA Immunotherapy (Biologic Therapy) Market by Country, 2019 - 2022, USD Million
TABLE 295 LAMEA Immunotherapy (Biologic Therapy) Market by Country, 2023 - 2030, USD Million
TABLE 296 LAMEA Chemotherapy Market by Country, 2019 - 2022, USD Million
TABLE 297 LAMEA Chemotherapy Market by Country, 2023 - 2030, USD Million
TABLE 298 LAMEA Hormonal Therapy Market by Country, 2019 - 2022, USD Million
TABLE 299 LAMEA Hormonal Therapy Market by Country, 2023 - 2030, USD Million
TABLE 300 LAMEA Oncology Drugs Market by Country, 2019 - 2022, USD Million
TABLE 301 LAMEA Oncology Drugs Market by Country, 2023 - 2030, USD Million
TABLE 302 Brazil Oncology Drugs Market, 2019 - 2022, USD Million
TABLE 303 Brazil Oncology Drugs Market, 2023 - 2030, USD Million
TABLE 304 Brazil Oncology Drugs Market by Indication, 2019 - 2022, USD Million
TABLE 305 Brazil Oncology Drugs Market by Indication, 2023 - 2030, USD Million
TABLE 306 Brazil Oncology Drugs Market by Drug Class Type, 2019 - 2022, USD Million
TABLE 307 Brazil Oncology Drugs Market by Drug Class Type, 2023 - 2030, USD Million
TABLE 308 Argentina Oncology Drugs Market, 2019 - 2022, USD Million
TABLE 309 Argentina Oncology Drugs Market, 2023 - 2030, USD Million
TABLE 310 Argentina Oncology Drugs Market by Indication, 2019 - 2022, USD Million
TABLE 311 Argentina Oncology Drugs Market by Indication, 2023 - 2030, USD Million
TABLE 312 Argentina Oncology Drugs Market by Drug Class Type, 2019 - 2022, USD Million
TABLE 313 Argentina Oncology Drugs Market by Drug Class Type, 2023 - 2030, USD Million
TABLE 314 UAE Oncology Drugs Market, 2019 - 2022, USD Million
TABLE 315 UAE Oncology Drugs Market, 2023 - 2030, USD Million
TABLE 316 UAE Oncology Drugs Market by Indication, 2019 - 2022, USD Million
TABLE 317 UAE Oncology Drugs Market by Indication, 2023 - 2030, USD Million
TABLE 318 UAE Oncology Drugs Market by Drug Class Type, 2019 - 2022, USD Million
TABLE 319 UAE Oncology Drugs Market by Drug Class Type, 2023 - 2030, USD Million
TABLE 320 Saudi Arabia Oncology Drugs Market, 2019 - 2022, USD Million
TABLE 321 Saudi Arabia Oncology Drugs Market, 2023 - 2030, USD Million
TABLE 322 Saudi Arabia Oncology Drugs Market by Indication, 2019 - 2022, USD Million
TABLE 323 Saudi Arabia Oncology Drugs Market by Indication, 2023 - 2030, USD Million
TABLE 324 Saudi Arabia Oncology Drugs Market by Drug Class Type, 2019 - 2022, USD Million
TABLE 325 Saudi Arabia Oncology Drugs Market by Drug Class Type, 2023 - 2030, USD Million
TABLE 326 South Africa Oncology Drugs Market, 2019 - 2022, USD Million
TABLE 327 South Africa Oncology Drugs Market, 2023 - 2030, USD Million
TABLE 328 South Africa Oncology Drugs Market by Indication, 2019 - 2022, USD Million
TABLE 329 South Africa Oncology Drugs Market by Indication, 2023 - 2030, USD Million
TABLE 330 South Africa Oncology Drugs Market by Drug Class Type, 2019 - 2022, USD Million
TABLE 331 South Africa Oncology Drugs Market by Drug Class Type, 2023 - 2030, USD Million
TABLE 332 Nigeria Oncology Drugs Market, 2019 - 2022, USD Million
TABLE 333 Nigeria Oncology Drugs Market, 2023 - 2030, USD Million
TABLE 334 Nigeria Oncology Drugs Market by Indication, 2019 - 2022, USD Million
TABLE 335 Nigeria Oncology Drugs Market by Indication, 2023 - 2030, USD Million
TABLE 336 Nigeria Oncology Drugs Market by Drug Class Type, 2019 - 2022, USD Million
TABLE 337 Nigeria Oncology Drugs Market by Drug Class Type, 2023 - 2030, USD Million
TABLE 338 Rest of LAMEA Oncology Drugs Market, 2019 - 2022, USD Million
TABLE 339 Rest of LAMEA Oncology Drugs Market, 2023 - 2030, USD Million
TABLE 340 Rest of LAMEA Oncology Drugs Market by Indication, 2019 - 2022, USD Million
TABLE 341 Rest of LAMEA Oncology Drugs Market by Indication, 2023 - 2030, USD Million
TABLE 342 Rest of LAMEA Oncology Drugs Market by Drug Class Type, 2019 - 2022, USD Million
TABLE 343 Rest of LAMEA Oncology Drugs Market by Drug Class Type, 2023 - 2030, USD Million
TABLE 344 Key information – AbbVie, Inc.
TABLE 345 Key Information – Amgen, Inc.
TABLE 346 key information – Astellas Pharma, Inc.
TABLE 347 KEY INFORMATION – AstraZeneca PLC
TABLE 348 Key Information – Bristol Myers Squibb Company
TABLE 349 Key Information – F. Hoffmann-La Roche Ltd.
TABLE 350 Key Information – Johnson & Johnson
TABLE 351 Key Information – Novartis AG
TABLE 352 Key Information - Merck & Co., Inc.
TABLE 353 Key Information – Pfizer, Inc.

List of Figures
FIG 1 Methodology for the research
FIG 2 Global Oncology Drugs Market, 2019 - 2030, USD Million
FIG 3 Key Factors Impacting Oncology Drugs Market
FIG 4 KBV Cardinal Matrix
FIG 5 Key Leading Strategies: Percentage Distribution (2019-2023)
FIG 6 Key Strategic Move: (Partnerships, Collaborations & Agreements : 2019, Mar – 2023, Nov) Leading Players
FIG 7 Porter’s Five Forces Analysis - Oncology Drugs Market
FIG 8 Global Oncology Drugs Market share by Indication, 2022
FIG 9 Global Oncology Drugs Market share by Indication, 2030
FIG 10 Global Oncology Drugs Market by Indication, 2019 - 2030, USD Million
FIG 11 Global Oncology Drugs Market share by Drug Class Type, 2022
FIG 12 Global Oncology Drugs Market share by Drug Class Type, 2030
FIG 13 Global Oncology Drugs Market by Drug Class Type, 2019 - 2030, USD Million
FIG 14 Global Oncology Drugs Market share by Region, 2022
FIG 15 Global Oncology Drugs Market share by Region, 2030
FIG 16 Global Oncology Drugs Market by Region, 2019 - 2030, USD Million
FIG 17 Recent strategies and developments: AbbVie, Inc.
FIG 18 Swot Analysis: AbbVie, Inc.
FIG 19 Swot Analysis: Amgen, Inc.
FIG 20 Recent strategies and developments: Astellas Pharma, Inc.
FIG 21 SWOT Analysis: Astellas Pharma, Inc.
FIG 22 Recent strategies and developments: AstraZeneca PLC
FIG 23 SWOT Analysis: AstraZeneca PLC
FIG 24 Recent strategies and developments: Bristol Myers Squibb Company
FIG 25 SWOT Analysis: Bristol Myers Squibb Company
FIG 26 Recent strategies and developments: F. Hoffmann-La Roche Ltd.
FIG 27 Swot Analysis: F. Hoffmann-La Roche Ltd.
FIG 28 Recent strategies and developments: Johnson & Johnson
FIG 29 Swot Analysis: Johnson & Johnson
FIG 30 SWOT Analysis: Novartis AG
FIG 31 Recent strategies and developments: Merck & Co., Inc.
FIG 32 SWOT Analysis: Merck & Co., Inc.
FIG 33 SWOT Analysis: Pfizer, Inc.